Safety and Efficacy of Carpal Stim in Treating Carpal Tunnel Syndrome
- Conditions
- Carpal Tunnel Syndrome
- Interventions
- Device: Sham stimulationDevice: PRF stimulation
- Registration Number
- NCT05497037
- Lead Sponsor
- GiMer Medical
- Brief Summary
The objective of this study is to assess the efficacy and safety of Carpal Stim for pain relief in CTS subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 58
-
Male or female subjects aged ≥ 20 years old during the recruitment phase
-
Clinical diagnosis of CTS:
- Diagnosis of CTS was confirmed by Nerve Conduction Velocity (NCV) but not limited to NCV
- Symptoms consistent with CTS for at least 3 months and the numerical rating scale (NRS) score ≥ 5 during the recruitment phase
-
Willing to abstain from any other treatment or therapy for CTS throughout the trial except protocol-described medications
-
The subject is willing and able to comply with the procedure and requirements of this trial
-
The participant is able to understand and provide informed consent, and has signed their written informed consent in accordance with IRB requirements
- Wrist fractures or cysts at the CTS affected side
- Wrist surgery within the past 3 months, especially carpal tunnel release surgery at the CTS affected side
- Receiving upper limb (including neck) surgery
- Injections of corticosteroids/cortisone into the wrist or hand within the past 3 months
- With a past medical history of diabetic polyneuropathy
- With a past medical history of rheumatoid arthritis
- With a past medical history of epilepsy
- Body Mass Index (BMI) > 40 kg/m2
- Participation in any investigational study in the last 2 weeks or current enrollment in any trial.
- Active infection at the stimulator contact site during the recruitment phase
- Pregnant women or diagnosed with postpartum edema in the wrist per investigator's discretion
- Patients with implanted medical devices that are electronic products, such as implantable cardioverter defibrillators, pacemakers, spinal cord stimulation systems, or spinal cord drug infusion pumps
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sham Control Group Sham stimulation Subject receiving fake stimulation (no stimulation but same device procedure with PRF group) PRF Group PRF stimulation Subject receiving 500 KHz PRF stimulation for 15 min
- Primary Outcome Measures
Name Time Method Safety: Incidence of adverse events (AEs) and serious AEs (SAEs) Up to 14 days Effectiveness: The responder rate of the PRF group and Sham-Control group 1 hour after end of stimulation Safety: Change in Nerve Conduction Velocity 14th day compared to baseline 14 days Median nerve sensory latency time change over 20%
- Secondary Outcome Measures
Name Time Method Change in PGIC scale in treatment and sham-controlled compared to baseline 1hr, 3, 7, 14 days after end of stimulation Proportion in responder in treatment and sham-controlled groups 3, 7, 14 days after end of stimulation Change in NRS score in treatment and sham-controlled groups compared to baseline 1hr, 3, 7, 14 days after end of stimulation Change in BCTQ-FSS score in treatment and sham-controlled compared to baseline 14 days after end of stimulation Change in GSS score in treatment and sham-controlled compared to baseline 1hr, 3, 7, 14 days after end of stimulation Change in BCTQ-SSS score in treatment and sham-controlled compared to baseline 14 days after end of stimulation
Trial Locations
- Locations (5)
Linkou Chang Gung Memorial Hospital
🇨🇳Taoyuan, Taiwan
Hualien Tzu Chi Hospital
🇨🇳Hualien City, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Veterans General Hospital-Taipei
🇨🇳Taipei, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan